Circulating Tumor Cells . Cancer Progression . Metastasis . Targeted Therapy
Next-Generation Sequencing . Microfluidics
Analysis of circulating tumor cells to dissect the biology of human cancer metastasis
More than 90% of cancer-related deaths, corresponding to more than eight million people worldwide each year, are due to the development of a metastatic disease.Clearly, these numbers reflect our limited understanding of the key processes that drive human cancer metastasis, and the need to develop new therapies that suppress the spread of cancer.
Several unsolved questions frame the metastasis research field, including the search of those molecular events that are fundamental for the metastatic process,and that would represent exceptional therapeutic targets. Cancer cells that leave the primary tumor site and are transported through the circulation to distant organs are referred to as circulating tumor cells (CTCs). CTCs are used as a noninvasive source of cancer cells for analysis of tumor genotypes (i.e. so-called liquid biopsy), yet their characterization is also an exceptional opportunity to dissect the biology of blood-borne metastasis. While CTCs are extraordinarily rare in circulation,even in patients with metastatic cancer (approximately one cancer cell among a billion normal blood cells), their isolation is highly dependent upon technological constraints. However, remarkable advances in the microfluidics field have now enabled the isolation of viable CTCs from virtually all cancer types, revealing highly unexpected features of the metastatic process.
For example, while the majority of CTCs circulate as single cells, they can also be found as clusters of 2–50 cells (a. k. a. CTC-clusters), with the ratio of single versus clustered CTCs varying significantly among different patients, and along disease progression. While CTC-clusters have been previously observed in human specimens, their role in the metastatic process was unknown. When combining microfluidic technologies for CTC isolation, single cell resolution RNA sequencing,patient samples and mouse models, we recently demonstrated that CTC-clusters represent key players in the metastatic process. First, we understood that the presence of CTC-clusters in the bloodstream of patients with breast and prostate cancer is associated with a shorter metastasis-free survival and overall survival,respectively, compared to patients in whom only single CTCs are found. Second,adopting multicolor mouse models to trace metastatic cancer cells in vivo, we concluded that CTC-clusters are oligoclonal units derived from the primary tumor(as opposed to be derived from intravascular aggregation events or the progeny of a single CTC), and that they are up to 50-fold more metastatic than single CTCs. Third, with a single cell-resolution RNA sequencing approach applied to human CTC-clusters and matched single CTCs from individual patients, we identified the cell-cell junction component plakoglobin to be required for CTC-clustering and metastasis. Together, these results highlight CTC-clusters as a previously unappreciated,yet potentially targetable mechanism of cancer dissemination.
Our research is now focused on the identification of the key vulnerabilities of CTC clusters.In collaboration with Prof. Christoph Rochlitz, Prof. Viola Heinzelmann Prof. Alfred Zippelius and Prof. Walter Weber at the University Hospital Basel we routinely isolate CTCs from the blood of patients with metastatic cancers. In the lab, we apply microfluidics technology to human and mouse blood specimens, and adopt next-generation sequencing, molecular and computational biology, CTC cultures as well as loss of function screenings in xenograft models. Together, our approach aims to gain fundamental insights into the biology of CTC-clusters, and to identify novel therapeutic targets to suppress the metastatic spread of cancer.
For more information, please visit the Cancer Metastasis Lab website.